211. Corynebacterium Bone and Joint Infection (BJI): A Retrospective Cohort Study in a Reference Center for BJI Management
Session: Poster Abstract Session: Clinical: Bone and Joint Infection
Thursday, October 5, 2017
Room: Poster Hall CD


 Corynebacterium is a rare etiologic agent of BJI. We aimed to describe this rare clinical condition and to assess treatment failure determinants.


All adult patients with proven Corynebacterium BJI (i.e. consistent clinical/radiological signs, AND ≥2 reliable positive bacteriological samples, AND treated as such) were included in a retrospective cohort study. After cohort description, determinants of treatment failure (i.e, infection persistence, relapse, requirement of additional surgical procedure, and BJI-related death) were determined using stepwise logistic regression and Kaplan Meier curve analysis.


The 51 included BJI were more frequently chronic (88.2%), orthopaedic device-related (ODI, 74.5%) and polymicrobial (78.4%). Surgery was performed in 92.2% of cases, and considered as appropriate in 76.5% of them. The main first-line antimicrobials were glycopeptides (68.6%), betalactams (50%) and/or clindamycin (10.0%). Three (5.9%) patients received daptomycin as part of first-line regimen, and 8 (15.7%) at any point of treatment. After a follow-up of 60.7 (IQR, 30.1-115.1) weeks, 20 (39.2%) treatment failures were observed, including 4 (20%) Corynebacterium-documented relapse. Independent risk factors were initial biological inflammatory syndrome (OR 16.1; p=0,030) and inappropriate surgical management (OR 7.481; p=0.036). Interestingly, all patients receiving daptomycin as part of first-line regimen failed (p<0.001), including one patient with a Corynebacterium-documented relapse with a daptomycin increased MIC. Among patients with ODI, survival curve analysis disclosed a worst prognosis in case of prosthetic joint infection (p=0.030), unappropriate surgical management (p=0.029) and daptomycin use as first-line regimen (p<0.001).


Corynebacterium BJI is a poorly known condition, frequently chronic and polymicrobial. An important rate of failure was observed, associated with inappropriate surgical management and daptomycin use as part of first-line regimen. As described for other clinical conditions such as infective endocarditis, daptomycin should be avoid or used in combination therapy to prevent resistance selection and treatment failure.



Tristan Ferry, MD, PhD1, Pierre Chauvelot, Resident2, Claire Triffault-Fillit, MD3, Evelyne Braun, MD3, Thomas Perpoint, MD4, Frederic Laurent, DPharm, PhD5, Michel-Henri Fessy, MD, PhD6, Sébastien Lustig, MD, PhD7, Christian Chidiac, MD, PhD3, Florent Valour, MD, PhD3 and Lyon BJI Study group, (1)Inserm 1111, UCBL1, Hospices Civils de Lyon, Lyon, France, (2)Hospices Civils de Lyon - Hôpital de la Croix-Rousse, Lyon, France, (3)ID Department, Regional Reference Center for Bji, Hospices Civils de Lyon, Lyon, France, (4)Hospices Civils de Lyon, Lyon, France, (5)Laboratory of Bacteriology, Regional Reference Center for Bji, Hospices Civils de Lyon, Lyon, France, (6)Hospices Civils de Lyon - Centre Hospitalier Lyon Sud, Pierre-Benite, France, (7)Orthopaedic Surgery, Regional Reference Center for Bji, Hospices Civils de Lyon, Lyon, France


T. Ferry, HERAEUS: Consultant , Speaker honorarium

P. Chauvelot, None

C. Triffault-Fillit, None

E. Braun, None

T. Perpoint, None

F. Laurent, None

M. H. Fessy, None

S. Lustig, Heraeus: Consultant , Consulting fee

C. Chidiac, None

F. Valour, None

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 4th with the exception of research findings presented at the IDWeek press conferences.